First chemical feature-based pharmacophore modeling of potent retinoidal retinoic acid metabolism blocking agents (RAMBAs): Identification of novel RAMBA scaffolds

Department of Pharmaceutical Sciences, Jefferson School of Pharmacy, Thomas Jefferson University, 130 South 9th Street, Philadelphia, PA 19107, USA.
European Journal of Medicinal Chemistry (Impact Factor: 3.43). 11/2011; 47(1):412-23. DOI: 10.1016/j.ejmech.2011.11.010
Source: PubMed

ABSTRACT The first three-dimensional (3D) pharmacophore model was developed for potent retinoidal retinoic acid metabolism blocking agents (RAMBAs) with IC(50) values ranging from 0.0009 to 5.84nM. The seven common chemical features in these RAMBAs as deduced by the Catalyst/HipHop program include five hydrophobic groups (hydrophobes), and two hydrogen bond acceptors. Using the pharmacophore model as a 3D search query against NCI and Maybridge conformational Catalyst formatted databases; we retrieved several compounds with different structures (scaffolds) as hits. Twenty-one retrieved hits were tested for RAMBA activity at 100nM concentration. The most potent of these compounds, NCI10308597 and HTS01914 showed inhibitory potencies less (54.7% and 53.2%, respectively, at 100nM) than those of our best previously reported RAMBAs VN/12-1 and VN/14-1 (90% and 86%, respectively, at 100nM). Docking studies using a CYP26A1 homology model revealed that our most potent RAMBAs showed similar binding to the one observed for a series of RAMBAs reported previously by others. Our data shows the potential of our pharmacophore model in identifying structurally diverse and potent RAMBAs. Further refinement of the model and searches of other robust databases is currently in progress with a view to identifying and optimizing new leads.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: All-trans retinoic acid (ATRA) is a derivative of retinol (or vitamin A) presenting similar benefits but considerable lower adverse toxicity, mainly in cases of high or long-term therapeutic doses. ATRA showed to be effective in the treatment and/or chemoprevention of several epithelial and hematological malignancies and diverse dermatological and eye diseases however, its low solubility in aqueous media and photosensitivity hinder its wider usage by the conventional administration methods. Supercritical fluids technologies are being widely used to enhance the in vivo bioactivity of this type of drugs both by improving their dissolution rate (using particle size reduction processes) and/or by controlling their release into the media after incorporation into solid polymeric/inorganic matrices (using supercritical impregnation/foaming processes). In both cases the solubility of the drug in the supercritical fluid (usually scCO2) is required for process optimization purposes. Therefore, in this work the solubility of ATRA in scCO2 was measured at different isotherms (308.2, 318.2 and 328.2 K) and pressures that ranged from 10 up to 30 MPa using a static analytical method. Solubility data were correlated using three commonly used density-based models, namely the Bartle, Chrastil and Méndez-Santiago-Teja models. The solubility of ATRA in scCO2 was found to be between 1.52 × 10−6 and
    Journal of Supercritical Fluids The 01/2015; 98. DOI:10.1016/j.supflu.2014.12.027 · 2.57 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The pharmacophore modeling in modern drug research has been applied for both bioactivity profiling and early stage of risk assessment of potential side effects and toxicity due to interactions of drug candidates with antitargets namely P-glycoprotein, hERG, cytochrome P450 and pregnane X-receptor. In this article, an existing state concerning with pharmacophore modeling applied for promiscuous proteins in drug research were updated and reviewed. In an attempt to create new safe medicines faster, the partial overlap of substrate properties of hERG, P-glycoprotein, pregnane X-receptor and cytochrome P450 has to be considered and drug safety has to be dealt on a system level on the off-targets.
    Current topics in medicinal chemistry 05/2013; DOI:10.2174/1568026611313090004 · 3.45 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this study, we suggest a workflow for the identification of potential leads targeted against poly(ADP-ribose) polymerase (PARP). To clarify the essential structure-activity relationship for the PARP inhibitors as well as identify potent leads against PARP, a qualitative pharmacophore model were established using a structure-based approach. The compounds in the Specs database were progressively filtered by the pharmacophore mapping, the rule of five, the molecular docking scores and the interactions with the critical active-site residues. The generated pharmacophore model consists of one hydrogen-bond acceptor feature, two hydrophobic features and the excluded volumes. It was validated using an internal database with a goodness of hit score of 0.87, and then utilized to screen the Specs database. Finally, nine structurally diverse compounds that showed better docking scores and the stronger interactions with the key amino acids were selected for further in vitro cytotoxicity assays. Biological evaluation indicated that all hits were found to be active with different degrees of inhibition at 40 μmol/L compound concentration. Compounds 2 (an IC50 value of 22 μM) and 4 (an IC50 value of 16 μM) exhibited moderate antiproliferative activities against MDA-MB-231 cancer cell line.
    Journal of the Taiwan Institute of Chemical Engineers 02/2015; 48. DOI:10.1016/j.jtice.2014.10.008 · 2.64 Impact Factor

Full-text (2 Sources)

Available from
May 28, 2014